LIDRW vs REGN · rev $202.0K vs P/E 14, rev $4.29B
AEye Inc (LIDRW) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
AEye Inc (LIDRW) common stock listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported LIDRW revenue for 2024-12-31 was $202.0K. Net income was -$35.5M. Revenue was down 86.2% from 2023-12-31 to 2024-12-31. LIDRW currently screens at market cap $0.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LIDRW currently screens at market cap $0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LIDRW and REGN stock pages for the full models.
Not investment advice.